Full Press Release Details
MARLBOROUGH, Mass. , Oct. 26, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates), all compared to the prior year period. The company reported GAAP earnings of $283 million or $0.20 per share (EPS), compared to GAAP earnings of $228 million or $0.17 a year ago, and achieved adjusted earnings per share of $0.31 for the period, compared to $0.27 a year ago.
"Our global team is delivering strong performance as we continue to invest in a deep and innovative portfolio and expand into faster-growing markets," said Mike Mahoney , chairman and chief executive officer of Boston Scientific. "We are grateful for our employees' commitment and winning spirit, particularly our team in Puerto Rico , which is working hard to address customer and patient needs in the wake of the recent hurricanes."
Third quarter financial results and recent developments:
| Net sales for the third quarter: | ||||||||||||||||||||
| Change | ||||||||||||||||||||
| Three Months Ended September 30, | As Reported Basis | Less: Impact of Foreign Currency | Operational Basis | |||||||||||||||||
| (in millions) | 2017 | 2016 | ||||||||||||||||||
| Interventional Cardiology | $ | 589 | $ | 568 | 3.8 | % | (0.4) | % | 4.2 | % | * | |||||||||
| Peripheral Interventions | 268 | 257 | 4.7 | % | (0.4) | % | 5.1 | % | ||||||||||||
| Cardiovascular | 857 | 825 | 4.1 | % | (0.4) | % | 4.5 | % | ||||||||||||
| Cardiac Rhythm Management | 463 | 467 | (0.6) | % | 0.3 | % | (0.9) | % | ||||||||||||
| Electrophysiology | 71 | 60 | 17.8 | % | 0.2 | % | 17.6 | % | ||||||||||||
| Rhythm Management | 534 | 527 | 1.5 | % | 0.3 | % | 1.2 | % | ||||||||||||
| Endoscopy | 403 | 367 | 9.8 | % | (0.2) | % | 10.0 | % | * | |||||||||||
| Urology and Pelvic Health | 274 | 248 | 10.3 | % | 0.1 | % | 10.2 | % | ||||||||||||
| Neuromodulation | 154 | 138 | 11.0 | % | 0.0 | % | 11.0 | % | ||||||||||||
| MedSurg | 831 | 753 | 10.2 | % | (0.1) | % | 10.3 | % | ||||||||||||
| Net Sales | $ | 2,222 | $ | 2,105 | 5.6 | % | (0.1) | % | 5.7 | % | ||||||||||
| *Interventional Cardiology grew 1.7% on an organic basis and Endoscopy grew 5.4% on an organic basis. | ||||||||||||||||||||
| Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | ||||||||||||||||||||
| Sales growth rates that exclude the impact of changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales are not prepared in accordance with U.S. GAAP. |
Guidance for Full Year and Fourth Quarter 2017
The company now estimates revenue for the full year 2017 to be in a range of $8.985 to $9.015 billion (compared to prior guidance of $8.890 to $8.990 billion ), which versus the prior year period, represents a growth range of approximately 7 to 8 percent on a reported basis and growth of approximately 7 percent on an operational basis including contribution of approximately 120 basis points from EndoChoice and Symetis. The company now estimates income on a GAAP basis in a range of $0.71 to $0.75 per share (compared to prior guidance of $0.70 to $0.74 per share) and now estimates adjusted earnings, excluding intangible asset impairment charges, acquisition-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, certain investment impairment charges and amortization expense, in a range of $1.24 to $1.27 per share (compared to prior guidance of $1.23 to $1.27 per share).
The company estimates sales for the fourth quarter of 2017 to be in a range of $2.345 to $2.375 billion , which versus the prior year period represents a growth range of approximately 7 to 8 percent on a reported basis and a growth range of approximately 5 to 6 percent on an operational basis including contribution of approximately 130 basis points from EndoChoice and Symetis. The company estimates earnings on a GAAP basis in a range of $0.19 to $0.23 per share. Adjusted earnings, excluding acquisition-related net charges, restructuring and restructuring-related net charges and amortization expense, are estimated in a range of $0.32 to $0.35 per share.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET) . The company will webcast the call to interested parties through its website: www.bostonscientific.com . Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend," "aiming" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates, GAAP earnings and adjusted earnings for the fourth quarter and full year 2017, our financial performance, our business plans and our positioning for revenue and earnings growth. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Use of Non-GAAP Financial Information A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to the end of this news release.
| CONTACT: | ||
| Media: | Kate Haranis | |
| 508-683-6585 (office) | ||
| Media Relations | ||
| Boston Scientific Corporation | ||
| [email protected] | ||
| Investors: | Susan Lisa, CFA | |
| 508-683-5565 (office) | ||
| Investor Relations | ||
| Boston Scientific Corporation | ||
| [email protected] |
| BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS (Unaudited) | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| in millions, except per share data | 2017 | 2016 | 2017 | 2016 | |||||||||
| Net sales | $ | 2,222 | $ | 2,105 | $ | 6,640 | $ | 6,195 | |||||
| Cost of products sold | 637 | 594 | 1,919 | 1,805 | |||||||||
| Gross profit | 1,585 | 1,511 | 4,721 | 4,390 | |||||||||
| Operating expenses: | |||||||||||||
| Selling, general and administrative expenses | 800 | 772 | 2,408 | 2,268 | |||||||||
| Research and development expenses | 254 | 232 | 734 | 664 | |||||||||
| Royalty expense | 16 | 20 | 50 | 59 | |||||||||
| Amortization expense | 139 | 136 | 424 | 408 | |||||||||
| Intangible asset impairment charges | 3 | 7 | 3 | 7 | |||||||||
| Restructuring charges (credits) | 12 | 5 | 17 | 22 | |||||||||
| Contingent consideration expense (benefit) | (4) | (13) | (78) | 23 | |||||||||
| Litigation-related charges (credits) | (12) | 4 | 196 | 632 | |||||||||
| 1,208 | 1,163 | 3,754 | 4,083 | ||||||||||
| Operating income (loss) | 377 | 348 | 967 | 307 | |||||||||
| Other income (expense): | |||||||||||||
| Interest expense | (57) | (58) | (172) | (175) | |||||||||
| Other, net | (11) | (33) | (89) | (44) | |||||||||
| Income (loss) before income taxes | 309 | 257 | 706 | 88 | |||||||||
| Income tax expense (benefit) | 26 | 29 | (13) | (135) | |||||||||
| Net income (loss) | $ | 283 | $ | 228 | $ | 719 | $ | 223 | |||||
| Net income (loss) per common share - basic | $ | 0.21 | $ | 0.17 | $ | 0.53 | 0.16 | ||||||
| Net income (loss) per common share - assuming dilution | $ | 0.20 | $ | 0.17 | $ | 0.52 | 0.16 | ||||||
| Weighted-average shares outstanding | |||||||||||||
| Basic | 1,372.0 | 1,360.6 | 1,369.1 | 1,356.1 | |||||||||
| Assuming dilution | 1,394.1 | 1,379.7 | 1,391.8 | 1,374.9 |
| BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| As of | |||||||
| September 30, | December 31, | ||||||
| in millions, except share data | 2017 | 2016 | |||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 210 | $ | 196 | |||
| Trade accounts receivable, net | 1,470 | 1,472 | |||||
| Inventories | 1,077 | 955 | |||||
| Deferred and prepaid income taxes | 76 | 75 | |||||
| Other current assets | 645 | 541 | |||||
| Total current assets | 3,478 | 3,239 | |||||
| Property, plant and equipment, net | 1,678 | 1,630 | |||||
| Goodwill | 6,882 | 6,678 | |||||
| Other intangible assets, net | 5,783 | 5,883 | |||||
| Other long-term assets | 815 | 666 | |||||
| TOTAL ASSETS | $ | 18,636 | $ | 18,096 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Current debt obligations | $ | 1,266 | $ | 64 | |||
| Accounts payable | 371 | 447 | |||||
| Accrued expenses | 2,551 | 2,312 | |||||
| Other current liabilities | 640 | 764 | |||||
| Total current liabilities | 4,828 | 3,587 | |||||
| Long-term debt | 4,416 | 5,420 | |||||
| Deferred income taxes | 66 | 18 | |||||
| Other long-term liabilities | 1,738 | 2,338 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity | |||||||
| Preferred stock, $0.01 par value - authorized 50,000,000 shares, | |||||||
| none issued and outstanding | |||||||
| Common stock, $0.01 par value - authorized 2,000,000,000 shares - | |||||||
| issued 1,620,302,039 shares as of September 30, 2017 and | |||||||
| 1,609,670,817 shares as of December 31, 2016 | 16 | 16 | |||||
| Treasury stock, at cost - 247,566,270 shares as of September 30, 2017 | |||||||
| and December 31, 2016 | (1,717) | (1,717) | |||||
| Additional paid-in capital | 17,125 | 17,014 | |||||
| Accumulated deficit | (7,785) | (8,581) | |||||
| Accumulated other comprehensive income (loss), net of tax | (51) | 1 | |||||
| Total stockholders' equity | 7,588 | 6,733 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 18,636 | $ | 18,096 |
| BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, 2017 | ||||||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per Share | ||||||||||||
| GAAP net income (loss) | $ | 309 | $ | (26) | $ | 283 | $ | 0.20 | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Intangible asset impairment charges | 3 | 0 | 3 | 0.00 | ||||||||||||
| Acquisition-related net charges (credits) (b) | 25 | (11) | 14 | 0.01 | ||||||||||||
| Restructuring and restructuring-related net charges (credits) (c) | 26 | (6) | 20 | 0.02 | ||||||||||||
| Litigation-related net credits (credits) | (12) | 2 | (10) | (0.01) | ||||||||||||
| Amortization expense | 139 | (17) | 122 | 0.09 | ||||||||||||
| Adjusted net income | $ | 490 | $ | (58) | $ | 432 | $ | 0.31 | ||||||||
| Three Months Ended September 30, 2016 | ||||||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per Share | ||||||||||||
| GAAP net income (loss) | $ | 257 | $ | (29) | $ | 228 | $ | 0.17 | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Intangible asset impairment charges | 7 | (1) | 6 | 0.00 | ||||||||||||
| Acquisition-related net charges (credits) (d) | (1) | (1) | (2) | (0.00) | ||||||||||||
| Restructuring and restructuring-related net charges (credits) (e) | 17 | (4) | 13 | 0.01 | ||||||||||||
| Litigation-related net charges (credits) | 4 | (1) | 3 | 0.00 | ||||||||||||
| Amortization expense | 136 | (16) | 120 | 0.09 | ||||||||||||
| Adjusted net income | $ | 420 | $ | (52) | $ | 368 | $ | 0.27 | ||||||||
| (a) Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." | ||||||||||||||||
| (b) In the third quarter of 2017, pre-tax acquisition-related net charges were $25 million, of which $8 million was recorded in cost of products sold, $14 million was recorded in selling, general and administrative expenses, $7 million was recorded to research and development expenses, $4 million was recorded as a benefit to contingent consideration. | ||||||||||||||||
| (c) In the third quarter of 2017, pre-tax restructuring charges were $12 million and pre-tax restructuring-related charges were $14 million, of which $11 million was recorded in cost of products sold and $3 million was recorded in selling, general and administrative expenses. | ||||||||||||||||
| (d) In the third quarter of 2016, pre-tax acquisition-related net credits were $1 million, of which $7 million was recorded in cost of products sold, $5 million was recorded in selling, general and administrative expenses and $13 million was recorded as a benefit to contingent consideration. | ||||||||||||||||
| (e) In the third quarter of 2016, pre-tax restructuring charges were $5 million and pre-tax restructuring-related charges were $12 million, of which $8 million was recorded in cost of products sold and $4 million was recorded in selling, general and administrative expenses. |
| Nine Months Ended September 30, 2017 | ||||||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per Share | ||||||||||||
| GAAP net income (loss) | $ | 706 | $ | 13 | $ | 719 | $ | 0.52 | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Intangible asset impairment charges | 3 | 0 | 3 | 0.00 | ||||||||||||
| Acquisition-related net charges (credits) (b) | (1) | (19) | (20) | (0.01) | ||||||||||||
| Restructuring and restructuring-related net charges (credits) (c) | 61 | (13) | 48 | 0.03 | ||||||||||||
| Litigation-related net charges (credits) | 196 | (73) | 123 | 0.09 | ||||||||||||
| Investment impairment charges (d) | 53 | (19) | 34 | 0.02 | ||||||||||||
| Amortization expense | 424 | (59) | 365 | 0.26 | ||||||||||||
| Adjusted net income | $ | 1,442 | $ | (170) | $ | 1,272 | $ | 0.91 | ||||||||
| Nine Months Ended September 30, 2016 | ||||||||||||||||
| in millions, except per share data | Pre-Tax | Tax Impact (a) | After-Tax | Impact per Share | ||||||||||||
| GAAP net income (loss) | $ | 88 | $ | 135 | $ | 223 | $ | 0.16 | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Intangible asset impairment charges | 7 | (1) | 6 | 0.00 | ||||||||||||
| Acquisition-related net charges (credits) (e) | 93 | (3) | 90 | 0.07 | ||||||||||||
| Restructuring and restructuring-related net charges (credits) (f) | 55 | (13) | 42 | 0.03 | ||||||||||||
| Litigation-related net charges (credits) | 632 | (228) | 404 | 0.29 | ||||||||||||
| Amortization expense | 408 | (54) | 354 | 0.26 | ||||||||||||
| Adjusted net income | $ | 1,283 | $ | (164) | $ | 1,119 | $ | 0.81 | ||||||||
| (a) Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." | ||||||||||||||||
| (b) In the first nine months of 2017, pre-tax acquisition-related net credits were $1 million, of which $18 million was recorded in cost of products sold, $35 million was recorded in selling, general and administrative expenses, $15 million was recorded to research and development expenses, $78 million was recorded as a benefit to contingent consideration, and $9 million of expense was recorded in other, net. | ||||||||||||||||
| (c) In the first nine months of 2017, pre-tax restructuring charges were $17 million and pre-tax restructuring-related charges were $44 million, of which $35 million was recorded in cost of products sold and $9 million was recorded in selling, general and administrative expenses. | ||||||||||||||||
| (d) Investment impairment charges are recorded in other, net. | ||||||||||||||||
| (e) In the first nine months of 2016, pre-tax acquisition-related net charges were $93 million, of which $39 million was recorded in cost of products sold, $31 million was recorded in selling, general and administrative expenses, and $23 million was recorded as contingent consideration expense. | ||||||||||||||||
| (f) In the first nine months of 2016, pre-tax restructuring charges were $22 million and pre-tax restructuring-related charges were $33 million, of which $20 million was recorded in cost of products sold and $13 million was recorded in selling, general and administrative expenses. |
| BOSTON SCIENTIFIC CORPORATION | ||||||
| CARDIAC RHYTHM MANAGEMENT (CRM) SALES BY COMPONENT | ||||||
| (Unaudited) | ||||||
| Three Months Ended September 30, | ||||||
| (in millions) | 2017 | 2016 | ||||
| Defibrillator systems | $ | 314 | $ | 311 | ||
| Pacemaker systems | 149 | 156 | ||||
| CRM products | $ | 463 | $ | 467 | ||
| Nine Months Ended September 30, | ||||||
| (in millions) | 2017 | 2016 | ||||
| Defibrillator systems | $ | 959 | $ | 956 | ||
| Pacemaker systems | 448 | 422 | ||||
| CRM products | $ | 1,407 | $ | 1,378 |
| BOSTON SCIENTIFIC CORPORATION SEGMENT, REGIONAL AND BUSINESS NET SALES (Unaudited) | ||||||||
| Q3 2017 Segment Net Sales as compared to Q3 2016 | ||||||||
| MedSurg | Cardiovascular | Rhythm Management | Total BSC | |||||
| Percentage change in net sales, as reported | 10.2 | % | 4.1 | % | 1.5 | % | 5.6 | % |
| Less: Impact of foreign currency fluctuations | (0.1) | % | (0.4) | % | 0.3 | % | (0.1) | % |
| Percentage change in net sales, operational | 10.3 | % | 4.5 | % | 1.2 | % | 5.7 | % |
| Less: Impact of significant acquisitions | 2.3 | % | 1.7 | % | 0.0 | % | 1.4 | % |
| Percentage change in net sales, organic | 8.0 | % | 2.8 | % | 1.2 | % | 4.3 | % |
| Q3 2017 Regional Net Sales as compared to Q3 2016 | ||||||||
| U.S. | Europe | AMEA | Emerging Markets | |||||
| Percentage change in net sales, as reported | 4.2 | % | 11.4 | % | 4.6 | % | 18.3 | % |
| Less: Impact of foreign currency fluctuations | 0.0 | % | 2.6 | % | (3.2) | % | 0.0 | % |
| Percentage change in net sales, operational | 4.2 | % | 8.8 | % | 7.8 | % | 18.3 | % |
| Less: Impact of significant acquisitions | 1.4 | % | 3.5 | % | 0.0 | % | 0.3 | % |
| Percentage change in net sales, organic | 2.8 | % | 5.3 | % | 7.8 | % | 18.0 | % |
| Q3 2017 Endoscopy Net Sales as compared to Q3 2016 | ||||||||
| Endoscopy | ||||||||
| Percentage change in net sales, as reported | 9.8 | % | ||||||
| Less: Impact of foreign currency fluctuations | (0.2) | % | ||||||
| Percentage change in net sales, operational | 10.0 | % | ||||||
| Less: Impact of significant acquisitions | 4.6 | % | ||||||
| Percentage change in net sales, organic | 5.4 | % | ||||||
| Q3 2017 Interventional Cardiology Net Sales as compared to Q3 2016 | ||||||||
| Interventional Cardiology | ||||||||
| Percentage change in net sales, as reported | 3.8 | % | ||||||
| Less: Impact of foreign currency fluctuations | (0.4) | % | ||||||
| Percentage change in net sales, operational | 4.2 | % | ||||||
| Less: Impact of significant acquisitions | 2.5 | % | ||||||
| Percentage change in net sales, organic | 1.7 | % |
| BOSTON SCIENTIFIC CORPORATION | ||||||||||||||
| ESTIMATED REVENUE NON-GAAP GROWTH RATES AND NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Q4 and Full Year 2017 Estimated Revenue Growth Rates | ||||||||||||||
| Q4 2017 Estimate | Full Year 2017 Estimate | Prior Full Year 2017 Estimate | ||||||||||||
| (Low) | (High) | (Low) | (High) | (Low) | (High) | |||||||||
| Estimated GAAP sales growth | 7 | % | 8 | % | 7 | % | 8 | % | 6 | % | 7 | % | ||
| Less: Estimated impact of foreign currency fluctuations | 2 | % | 2 | % | 0 | % | 1 | % | 0 | % | (1) | % | ||
| Estimated sales growth, operational* | 5 | % | 6 | % | 7 | % | 7 | % | 6 | % | 8 | % | ||
| * Includes contribution of approximately 130 basis points for the fourth quarter and 120 basis points for the full year from EndoChoice and Symetis. Prior Full Year 2017 Estimate includes contribution of approximately 120 basis points from EndoChoice and Symetis. | ||||||||||||||
| Q4 and Full Year 2017 EPS Guidance | ||||||||||||||
| Q4 2017 Estimate | Full Year 2017 Estimate | Prior Full Year 2017 Estimate | ||||||||||||
| (Low) | (High) | (Low) | (High) | (Low) | (High) | |||||||||
| GAAP results | $ | 0.19 | $ | 0.23 | $ | 0.71 | $ | 0.75 | $ | 0.70 | $ | 0.74 | ||
| Estimated acquisition-related net charges | 0.02 | 0.01 | 0.01 | — | 0.01 | 0.01 | ||||||||
| Estimated restructuring and restructuring-related charges | 0.02 | 0.02 | 0.06 | 0.06 | 0.05 | 0.05 | ||||||||
| Estimated amortization expense | 0.09 | 0.09 | 0.35 | 0.35 | 0.35 | 0.35 | ||||||||
| Litigation-related charges | 0.00 | 0.00 | 0.09 | 0.09 | 0.10 | 0.10 | ||||||||
| Investment impairment charges | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.02 | ||||||||
| Adjusted results | $ | 0.32 | $ | 0.35 | $ | 1.24 | $ | 1.27 | $ | 1.23 | $ | 1.27 | ||
| Prior Guidance Estimate - Q3 2017 QTD | ||||||||||||||
| (Low) | (High) | |||||||||||||
| GAAP results | $ | 0.16 | $ | 0.18 | ||||||||||
| Estimated acquisition-related net charges | 0.02 | 0.02 | ||||||||||||
| Estimated restructuring and restructuring-related charges | 0.02 | 0.02 | ||||||||||||
| Estimated amortization expense | 0.09 | 0.09 | ||||||||||||
| Adjusted results | $ | 0.29 | $ | 0.31 |
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts, and operational net sales, which exclude the impact of changes in foreign currency exchange rates, and organic net sales, which exclude the impact of foreign currency exchange rates and the impact of recent acquisitions with significant sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States .
The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate operational net sales which exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this constant currency growth rate and/or growth rates excluding the impacts of recent acquisitions with significant sales is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.
The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures for the three and nine months ended September 30, 2017 and 2016 and for the forecasted three month period and full year ending December 31, 2017, as well as reasons for excluding each of these individual items:
Adjusted Net Income and Adjusted Net Income per Share:
Operational Net Sales Exclude the Impact of Changes in Foreign Currency Exchange Rates and/or the Impact of Recent Acquisitions with Significant Sales
Adjusted net income and adjusted net income per share that exclude certain amounts and operational net sales which exclude the impact of changes in foreign currency exchange rates and/or the impacts of recent acquisitions with significant sales, are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.
SOURCE Boston Scientific Corporation